So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

These schemes are aimed at protecting and encouraging domestic ingredient manufacturing which is seen as a critical step in ...

The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Drawing on his decades-long experience at the intersection of politics and economics, he now unpacks what the new phase of ...

Instead of battling over tariffs, Washington and Beijing have turned to a potentially far more harmful strategy: flexing ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed ...